Streptococcus salivarius for enhancing anti-infection ability of targeted regulation host antibacterial peptide

By targeting the regulation of the expression of Streptococcus salivary CCFM1416, which regulates the expression of the host antibacterial peptide, the problem of insufficient immune regulation of oral symbiotic bacteria in the prevention of oral pathogenic bacteria in the prior art is solved, and the host oral mucosal immune defense has been enhanced, which has significantly improved the Resistance of oral pathogenic bacteria.

CN118995514APending Publication Date: 2024-11-22JIANGNAN UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411225194.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-03
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

The prior art lacks effective regulation of host oral immunity in the application of oral symbiotic bacteria, and it is difficult to effectively prevent oral pathogenic bacteria infection.

Method used

Provide a CCFM1416, a salivary streptococcal strain CCFM1416, targeted to regulate the expression of the host antimicrobial peptide, enhance the local immune defense of the oral cavity and related mucosa, and prepares its live cells, inactivated cells, fermentation broth or lysate for use in Microbial preparations are prepared to enhance the host's anti-infection ability.

Benefits of technology

Streptococcus salivary CCFM1416 can promote the expression of the antimicrobial peptide HBD-2 in oral epithelial cells, activate the anti-infection pathways of TLR2/Myd88 and IL-17/IKBζ, upregulate the expression of the antimicrobial peptide DEFB3, and reduce the pathogenic bacteria Candida albicans on the host tongue tissue. Adhesion improves oral pathological conditions and significantly improves the host's resistance to oral pathogenic bacteria.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118995514A_ABST
    Figure CN118995514A_ABST
Patent Text Reader

Abstract

The invention discloses a streptococcus salivarius for enhancing the anti-infection ability of a targeted regulation host antibacterial peptide, and belongs to the technical field of microorganisms. The streptococcus salivarius is separated from saliva samples of healthy people, has the capability of regulating and controlling host immunity to improve pathogenic bacterium infection resistance of the oral cavity of a host, and is specifically reflected in that (1) expression of oral epithelial cell antibacterial peptide HBD-2 is promoted; (2) the protein expression level of the antibacterial peptide HBD-2 in the tongue tissue of the mouse is improved; (3) activating channels TLR2 / Myd88 and IL-17 / IKB zeta for resisting pathogenic bacteria infection; (4) reducing the load capacity of candida albicans in tongue tissues of the mouse; (5) improving pathological conditions of tongue tissues of individuals; and (6) the invasion of oral pathogen Candida albicans to tongue tissues of mice is improved. Therefore, the streptococcus salivarius has a huge application prospect in products for regulating and controlling the oral immunity of the host and improving the anti-infection capability of the oral cavity of the host.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to a strain of Streptococcus salivarius which targets and regulates host antimicrobial peptides to enhance the anti-infection ability thereof, and belongs to the technical field of microorganisms. Background Art

[0002] Airborne particles, symbiotic microorganisms, and food first come into contact with the oral cavity before entering the gastrointestinal tract or respiratory tract. The oral mucosa is composed of stratified squamous epithelium with different characteristics, which vary at different physiological and anatomical sites in the oral cavity. The oral epithelial barrier isolates the host from the environment and is the first line of defense against pathogens, exogenous substances, and mechanical stress. The epithelial cells, endothelial cells, fibroblasts, and immune cells in the oral mucosal tissue work together to maintain the host's oral health. Host antimicrobial peptides (AMPs) are an important component of the body's immune system and have broad-spectrum antibacterial, antiviral, and antifungal activities. They not only directly kill pathogenic microorganisms, but also enhance the host's infection defense capabilities through multiple mechanisms such as regulating immune responses and promoting tissue repair. Especially on mucosal surfaces such as the oral cavity, the role of antimicrobial peptides is particularly critical and can effectively prevent the invasion and colonization of pathogens. Dommisch et al. showed that α-defensins, β-defensins, LL-37, calprotectin and other antimicrobial proteins present in the oral cavity play an important role in maintaining oral health and preventing the adhesion and infection of oral bacteria, fungi and viruses. Normal human oral keratinocytes can express the antimicrobial peptide HBD-2, and the microbial-associated molecular patterns of commensal bacteria are good inducers of HBD-2 expression in oral epithelial cells, indicating that oral commensal bacteria can regulate the host innate immune response and maintain the homeostasis between host oral health and balance.

[0003] The oral microbiome is the second largest microbial community after the human intestine. The interaction between oral microorganisms and the host jointly maintains the dynamic balance of the host's oral microecology. There have been many reports on the use of probiotics in the treatment or relief of periodontitis, gingivitis, dental caries, halitosis and a series of oral mucosal diseases, but most of these probiotics come from the intestine. Recent studies have shown that probiotics from the intestine may produce acid in the mouth, which increases the risk of caries, while commensal bacteria from the oral habitat can not only colonize in the mouth more easily, but also as microorganisms of the original ecological site of the oral cavity, they do not produce strong acid. Streptococcus salivarius is a commensal bacterium widely present in the oral microbiome. Dale et al. showed that some commensal bacteria can regulate the host's immune system, including regulating the expression of antimicrobial peptides. These strains directly contact the host mucosa, stimulate local immune responses, enhance the synthesis and release of antimicrobial peptides, and thus improve the host's resistance to oral and pharyngeal infections. At present, the application of oral commensal bacteria mainly focuses on direct antibacterial effects, but lacks the regulation of the host's oral immunity. Therefore, it is particularly important to link oral commensal bacteria with the host's innate immunity, enhance the host's oral immunity, and prevent oral pathogenic bacteria infections. Summary of the invention

[0004] Based on the above background, the technical goal of this patent is to provide a strain of Streptococcus salivarius that targets and regulates the expression of host antimicrobial peptides, and explore its application potential in improving the host's ability to resist infection. This strain of Streptococcus salivarius will regulate the secretion of antimicrobial peptides and enhance the local immune defense of the oral cavity and related mucosa, providing a new and biosafe solution for infection prevention and treatment.

[0005] The present invention provides a strain of Streptococcus salivarius CCFM1416, which was deposited in Guangdong Provincial Microbiological Culture Collection Center on August 2, 2024, with a deposit number of GDMCC No: 64941.

[0006] In one embodiment of the present invention, the Streptococcus salivarius CCFM1416 is isolated from saliva samples of healthy people and has the following characteristics:

[0007] The colonies of the Streptococcus salivarius CCFM1416 after inoculation on the MRS solid culture medium and cultured for 48 hours are generally white protrusions, round, smooth and moist surface, and neat edges; the Streptococcus salivarius CCFM1416 is a Gram-positive bacterium, facultative anaerobic, with an optimal growth temperature of 35-40° C. and an optimal growth pH of 6.0-7.0.

[0008] The present invention also provides a postbiotic prepared by using Streptococcus salivarius CCFM1416, wherein the postbiotic comprises the inactivated bacteria of Streptococcus salivarius CCFM1416 according to claim 1 and / or its lysate.

[0009] The invention also provides a microbial preparation containing the Streptococcus salivarius CCFM1416.

[0010] In one embodiment of the present invention, the microbial preparation includes living cells, inactivated cells, fermentation broth, lysate or metabolites of the Streptococcus salivarius CCFM1416.

[0011] In one embodiment of the present invention, when the microbial preparation contains live cells, inactivated cells or fermentation broth of the Streptococcus salivarius CCFM1416, the content of the Streptococcus salivarius CCFM1416 in the microbial preparation is not less than 1×10 6 CFU / mL or 1×10 6 CFU / g.

[0012] The present invention also provides a product containing the Streptococcus salivarius CCFM1416, or the postbiotics, or the microbial preparation.

[0013] In one embodiment of the present invention, the product is a health product, a medicine or a daily chemical product.

[0014] In one embodiment of the present invention, the conventional auxiliary materials include one or more of fillers, flavoring agents, binders, disintegrants, lubricants, antacids, and nutritional enhancers.

[0015] In one embodiment of the present invention, the health product comprises the Streptococcus salivarius CCFM1416 and conventional auxiliary materials.

[0016] In one embodiment of the present invention, the conventional auxiliary materials include one or more of fillers, flavoring agents, binders, disintegrants, lubricants, antacids, and nutritional enhancers.

[0017] In one embodiment of the present invention, the medicine comprises the Streptococcus salivarius CCFM1416 and a pharmaceutically acceptable carrier.

[0018] In one embodiment of the present invention, the carrier includes one or more of fillers, binders, wetting agents, disintegrants, lubricants, and flavoring agents commonly used in medicine.

[0019] In one embodiment of the present invention, the daily chemical products include toothpaste, mouthwash and oral spray.

[0020] The present invention also provides the use of the Streptococcus salivarius CCFM1416, or the postbiotic, or the microbial preparation in the preparation of medicines for preventing and / or treating pathogenic bacteria infection.

[0021] In one embodiment of the present invention, the pathogenic bacteria include Candida albicans.

[0022] In one embodiment of the present invention, the prevention and / or treatment of pathogenic bacterial infection comprises:

[0023] Promoting the expression of antimicrobial peptides; the antimicrobial peptides include HBD-2 and DEFB3;

[0024] and / or, activate the expression of TLR2 / Myd88 / IKBζ anti-infection pathway;

[0025] and / or, activate the expression of the IL-17 / IKBζ anti-infection pathway;

[0026] and / or, reducing the pathogenic bacterial load;

[0027] and / or, improving the pathological condition at the site of infection.

[0028] In one embodiment of the present invention, the infection site includes the oral cavity.

[0029] Beneficial Effects

[0030] The present invention provides a strain of Streptococcus salivarius CCFM1416, which is isolated from oral saliva samples of healthy people. The strain has the function of targeted regulation of host antimicrobial peptide expression and enhancement of host oral mucosal innate immunity, which is specifically embodied in:

[0031] (1) Promote the expression of antimicrobial peptide HBD-2 in oral epithelial cells;

[0032] (2) Activate the expression of TLR2 / Myd88 / IKBζ anti-infection pathway in the host:

[0033] (3) Activate the expression of IL-17 / IKBζ anti-infection pathway in the host

[0034] (4) Upregulate the expression of antimicrobial peptide DEFB3 in the host;

[0035] (5) Improve the manifestation of individual oral pathology;

[0036] (6) Reduce the adhesion of pathogenic bacteria Candida albicans to the host tongue tissue.

[0037] Therefore, Streptococcus salivarius CCFM1416 has great application prospects in products that regulate host oral immunity and resist oral pathogenic bacteria infections. BRIEF DESCRIPTION OF THE DRAWINGS

[0038] Figure 1 :Effects of different bacterial lysates on HBD-2 expression in oral epithelial cells (HOK-16B);

[0039] Figure 2 :Flowchart of animal experiment design;

[0040] Figure 3 :Changes in the tongue mucosa of mice after intervention with Streptococcus salivarius;

[0041] Figure 4 :The effect of Streptococcus salivarius on the load of Candida albicans in the tongue tissue of mice;

[0042] Figure 5 :Effects of Streptococcus salivarius on activation of anti-infection pathways in mouse tongue tissue;

[0043] Figure 6 :Effects of Streptococcus salivarius on DEFB3 expression in mouse tongue tissue;

[0044] Figure 7 :Histopathological evaluation of mouse tongue;

[0045] Figure 8 : Pathological evaluation of PAS staining of mouse tongue tissue.

[0046] Biomaterial Deposit

[0047] A strain of Streptococcus salivarius CCFM1416, taxonomically named Streptococcus salivarius, was deposited in the Guangdong Provincial Microbiological Culture Collection on August 2, 2024, with the deposit number GDMCC No: 64941. The deposit address is the 5th Floor, Building 59, No. 100 Xianlie Middle Road, Guangzhou, Institute of Microbiology, Guangdong Academy of Sciences. DETAILED DESCRIPTION

[0048] To make the purpose, technical scheme and advantages of the present invention clearer, the present invention is further described in detail below in conjunction with specific embodiments and with reference to the accompanying drawings. The strains, cells and animals involved in the following embodiments are as follows: SPF-grade BALB / c mice, female, 6 weeks old, weighing 15-18g, purchased from Beijing Weitong Lihua Experimental Animal Technology Co., Ltd. (Production License No. SCXK (Beijing) 2012-0001). Salivarius Streptococcus OJSWX12B1 comes from the strain bank of the Biotechnology Center of Jiangnan University. Candida albicans SC5314 was purchased from Ningbo Mingzhou Technology Co., Ltd. Human oral keratinocytes HOK-16B were purchased from Qingqi (Shanghai) Biotechnology Development Co., Ltd.

[0049] The culture medium involved in the following examples is as follows:

[0050] BHI liquid medium: peptone 10.0 g / L, dehydrated calf brain extract powder 12.5 g / L, dehydrated bull heart extract powder 5.0 g / L, sodium chloride 5.0 g / L, glucose 2.0 g / L, disodium hydrogen phosphate 2.5 g / L, pH 7.2-7.4;

[0051] BHI solid medium: peptone 10.0 g / L, dehydrated calf brain extract powder 12.5 g / L, dehydrated ox heart extract powder 5.0 g / L, sodium chloride 5.0 g / L, glucose 2.0 g / L, disodium hydrogen phosphate 2.5 g / L, agar 20.0 g / L, pH 7.2-7.4;

[0052] Complete cell culture medium: 89% (v / v) DMEM medium + 10% (v / v) fetal bovine serum + 1% (v / v) 100× penicillin and streptomycin mixed solution (penicillin content in the mixed solution is 10000U / mL, streptomycin concentration is 10mg / mL), which is the cell culture medium for human oral keratinocytes HOK-16B.

[0053] The bacterial liquid involved in the following examples is as follows:

[0054] Preparation of Streptococcus bacterial solution:

[0055] (1) Preparation of seed solution:

[0056] Use a sterile inoculation loop to dip a small amount of Streptococcus salivarius CCFM1416 and OJSWX12B1 bacterial liquid into BHI solid medium for activation and culture at 37°C for 48 hours. Then pick a single colony and inoculate it into BHI liquid medium and culture it in a 37°C incubator for 18 hours to prepare the seed liquid.

[0057] (2) The prepared seed solution was inoculated in BHI liquid medium at a 2% (v / v) inoculation rate, cultured in a 37°C incubator for 18 h, centrifuged and concentrated to collect the bacteria and count the colonies, and stored in a -80°C refrigerator with 30% glycerol for animal experiments. Before intervention, the glycerol was removed by centrifugation and the concentration of the bacterial suspension was adjusted to 1×10 10 CFU / mL.

[0058] Bacterial lysis buffer:

[0059] (1) According to the preparation method of Streptococcus salivarius bacterial liquid, the bacterial liquid was centrifuged to obtain bacterial slurry, and the concentration of the suspension was adjusted to 5×10 9 CFU / mL, homogenized in a high-pressure homogenizer (800-1200 MPa) for 10 times, and filtered with a 0.22 μm filter membrane to obtain the bacterial lysate prepared from the bacterial suspension of the corresponding concentration.

[0060] (2) Preparation of cell culture medium containing 5% (v / v) Streptococcus salivarius cell lysate:

[0061] The bacterial lysate obtained above was added to a complete cell culture medium at a ratio of 5% (v / v) to obtain a cell culture medium containing the bacterial lysate, which included 84% (v / v) DMEM culture medium + 10% (v / v) fetal bovine serum + 1% (v / v) 100× penicillin and streptomycin mixed solution (the penicillin content in the mixed solution was 10000 U / mL, and the streptomycin concentration was 10 mg / mL) + 5% (v / v) Streptococcus salivarius bacterial lysate.

[0062] Candida albicans suspension:

[0063] (1) Preparation of seed solution:

[0064] Candida albicans SC5314 was inoculated into YPD medium and cultured in a shaking incubator at 28°C for 18 h to prepare a seed solution.

[0065] (2) The Candida albicans seed solution was inoculated into YPD medium at a 2% inoculum volume, and after incubation at 28°C for 18 h, the cells were collected by centrifugation and resuspended in sterile saline to a concentration of 1×10 7 CFU / mL.

[0066] Embodiment 1: separation and identification of Streptococcus salivarius CCFM1416

[0067] The specific steps are as follows:

[0068] Collect non-irritated saliva from healthy people and store it in 30% glycerol in a -80℃ refrigerator or place the sample in dry ice and transfer it to the laboratory for immediate bacterial isolation and culture. After the sample is thawed, pipette 0.2mL into 1.8mL sterile saline to obtain 10 -1 Dilution, then draw 0.5mL 10 -1 Dilute in 4.5 mL of saline to obtain 10 -2 Dilution, follow this procedure to obtain 10 -3 , 10 -4 , 10 -5 , 10 -6 Gradient dilution. Take 10 -4 , 10 -5 , 10 -6 Place 1 mL of each dilution in a plate, pour into BHI solid culture medium, mix gently, and after the culture medium solidifies, invert and culture at 37°C for 48 h.

[0069] Select colonies of different morphologies and streak them on BHI plates for purification. Pick the purified single colony and inoculate it into 10mL liquid culture medium and culture it at 37℃ for 18h. Take 1.0mL of cultured bacterial solution, centrifuge it at 5000r / min for 3min, discard the supernatant, add 1.0mL of sterile saline to wash 3 times, resuspend it in 1.0mL of sterile water, and use it as a template for bacterial identification. Set up a PCR system with a volume of 20μL, add 0.5μL forward primer (10μM), 0.5μL reverse primer (10μM), 10μL 2×TaqMixture, 0.5μL bacterial suspension, and 8.5μL double distilled water. Primer information is shown in Table 1.

[0070] Table 1: Primer information

[0071]

[0072]

[0073] For the correctly identified strains, 1.0 mL of bacterial solution was taken into a 2 mL bacterial preservation tube, centrifuged at 6000 r / min for 3 min, the supernatant was removed in a clean bench, 1 mL of 30% sterile glycerol was added, the mixture was thoroughly mixed with a vortex oscillator, and then stored in a -80°C refrigerator. The 16S sequence information is shown in SEQ ID NO.1.

[0074] The obtained 16S sequence was confirmed by NCBI BLAST (http: / / www.ncbi.nlm.nih.gov / BLAST). The closer the Query Cover and Identification are to 100%, the more feasible it is. If there are multiple species in the comparison results, the Complete genome species will be prioritized while taking the numerical values ​​into consideration. The results showed that the strain was Streptococcus salivarius, named Streptococcus salivarius CCFM1416.

[0075] Example 2: Ability of Streptococcus salivarius cell lysate to promote the expression of antimicrobial peptide HBD-2 in oral epithelial cells

[0076] The specific steps are as follows:

[0077] Oral epithelial HOK-16B cells were revived and passaged three times, and the cell concentration was adjusted to 5×10 5 / mL, inoculate 2mL of the cell suspension at this concentration in a 6-well cell culture plate, incubate for 24h under 5% CO2, 37℃, and then add sample intervention. Set up a control group and a strain sample treatment group. The control group was added with cell culture solution containing 5% PBS; the strain sample treatment group was added with cell culture solution containing 5% bacterial lysis solution, and 3 replicates were set in each group. After 24h of intervention, the cell supernatant was collected in the 6-well plate, and the secretion of antimicrobial peptide HBD-2 in the supernatant was detected according to the instructions of the Elisa kit.

[0078] Table 2: Group information table

[0079]

[0080] The results are as follows Figure 1 As shown in the results, after 24 hours of intervention, the content of HBD-2 in the supernatant of the blank group was 336.71pg / mg, and the content of HBD-2 in the CCFM 1416 bacterial lysate group (CCFM 14166-P) was 442.80pg / mg compared with the blank control group, which could significantly upregulate the expression of antimicrobial peptide HBD-2 in oral epithelial cells (p < 0.01); while there was no significant difference between the OJSWX12B1 bacterial lysate group (OJSWX12B1-P) and the blank control group. Therefore, at the cellular level, CCFM 1416-P can promote the expression of antimicrobial peptide HBD-2 in oral epithelial cells, regulate host innate immunity, and enhance the host's ability to resist pathogenic bacteria infection.

[0081] Example 3: Application of Streptococcus salivarius CCFM 1416 in regulating host immunity

[0082] 1. Preparation of Streptococcus salivarius suspension

[0083] Preparation of Streptococcus salivarius CCFM1416 bacterial suspension: Use a sterile inoculation loop to dip a small amount of Streptococcus salivarius CCFM1416 bacterial suspension into BHI solid medium for activation, and culture at 37°C for 48 hours. Then pick a single colony and inoculate it into BHI liquid medium, and culture it in a 37°C incubator for 18 hours to prepare the seed solution.

[0084] The prepared seed solution was inoculated in BHI liquid medium at 2% (v / v) inoculation volume, cultured in a 37°C incubator for 18 h, centrifuged and concentrated to collect the bacteria and count the colonies, and stored in a -80°C refrigerator with 30% glycerol for later use. Before intervention, the glycerol was removed by centrifugation and the concentration of the bacterial suspension was adjusted to 1×10 10 CFU / mL.

[0085] 2. Experimental animals and strains:

[0086] SPF BALB / c mice, female, 6 weeks old, weighing 15-18 g, were purchased from Beijing Weitong Lihua Experimental Animal Technology Co., Ltd. (Production License No. SCXK (Beijing) 2012-0001). Salivarius CCFM1416 was from the strain bank of the Biotechnology Center of Jiangnan University. Candida albicans SC5314 was purchased from Ningbo Mingzhou Technology Co., Ltd. Figure 2 Table 3 shows the animal experiment process.

[0087] Table 3: Animal experimental plan and grouping

[0088]

[0089] Before the experiment, all mice were randomly divided into 3 groups according to their body weight, and the mice were placed in an environment with a 22℃-24℃ and 12-hour light-dark cycle to adapt for one week. Referring to Table 2, all groups of mice were fed normally throughout the experiment. The blank group mice were treated with normal saline instead of probiotics throughout the experiment, and immunosuppressants were injected on the 14th and 16th days. The Candida albicans model group was treated with normal saline instead of probiotics on days 0-17, and immunosuppressants were injected on the day before and after Candida albicans infection (the infection method of Candida albicans was: anesthetizing mice, soaking cotton balls of the same size in a concentration of 1×10 7 CFU / ml of Candida albicans suspension was then inoculated under the tongue of mice for about 60 minutes. The intervention group was continuously intervened with Streptococcus salivarius CCFM1416 for 17 days (days 0 to 17), immunosuppressants were injected on days 14 and 16, and Candida albicans infection was performed on day 15. The specific operation method of all interventions was oral irrigation with a No. 8 gavage needle.

[0090] The specific steps are as follows:

[0091] (1) Intervention experiment: Starting from day 0, the details are as follows:

[0092] Blank control group: Use No. 8 elbow gavage needle to draw 30ul of sterile saline for oral irrigation once a day.

[0093] Model group mice: Use a No. 8 elbow gavage needle to draw 30ul of sterile saline for oral irrigation once a day.

[0094] S. salivarius CCFM1416 group: 30ul of S. salivarius CCFM1416 bacterial suspension (1×10 10 CFU / mL) for oral rinse once a day.

[0095] (2) Immunosuppression: All groups of mice were immunosuppressed on days 14 and 16 by subcutaneous injection of 0.2 ml of 225 mg / kg cortisone acetate.

[0096] (3) Infection experiment (modeling period): All groups except the blank group were anesthetized on the 15th day and soaked in 1×10 7 CFU / mL of Candida albicans suspension was then inoculated sublingually in mice for about 60 minutes, and then the cotton ball was removed.

[0097] After the intervention, the tongue tissue of mice was sampled for subsequent tissue pathogen load, HE tissue pathology analysis, PAS pathogen hyphae invasion analysis, and detection of the expression levels of related antibacterial indicators in the tongue tissue.

[0098] 3. Experimental results:

[0099] (1) Changes in the mucosal surface of mouse tongue

[0100] After the intervention, the surface of the tongue mucosal tissue of mice in each group was observed to evaluate the infection degree of Candida albicans in the oral cavity. Figure 3 As shown in the figure, the back of the tongue of the mice in the control group was light red, the tongue was smooth and moist, and there was no colonization of pathogenic bacteria Candida albicans; the tongue of the mice in the model group was covered with a thick pseudomembrane formed by Candida albicans, which adhered to the surface of the mouse tongue in pieces, and the mouse tongue showed symptoms of atrophy. After the intervention of Streptococcus salivarius CCFM1416, the colonization of Candida albicans on the mucosal surface of the mouse tongue was greatly reduced compared with the model group, and only a few points had pseudomembranes of Candida albicans. The appearance of the mouse tongue tissue was similar to that of the blank group mice, indicating that Streptococcus salivarius CCFM1416 can resist the colonization of Candida albicans in the oral cavity to a large extent and play a role in resisting pathogenic bacteria infection in the host's oral cavity.

[0101] (2) Candida albicans load in mouse tongue tissue

[0102] After the intervention, the tongue tissues of mice were homogenized and counted to assess the colonization of Candida albicans in the tongue tissues. Figure 4 As shown in Figure 2, the average colonization of Candida albicans in the tongue tissue of mice in the model group was about 7.52×10 5 CFU / g; the load of pathogenic bacteria Candida albicans in tongue tissue of Streptococcus salivarius CCFM1416 group after intervention was about 1.05×10 5 CFU / g showed a significant downward trend compared with the model group (P<0.05). Therefore, S. salivarius CCFM1416 can reduce the colonization of pathogenic bacteria Candida albicans in the oral cavity of mice and play an anti-pathogenic bacterial infection role.

[0103] (3) Expression of anti-infection pathways in mouse tongue tissue

[0104] Microbial-associated molecular patterns can bind to relevant receptors of the host oral epithelial cells and activate the expression of downstream antibacterial substances, such as the TLR2 / Myd88 pathway. In addition, the activation of the IL-17 / IKBζ pathway is crucial for the mouse oral resistance to pathogenic bacteria infection. The upregulation of IL-17 will activate the expression of the NF-κB non-classical pathway protein IKBζ in oral epithelial cells, thereby upregulating the expression of the downstream product antimicrobial peptide DEFB3, thereby playing a role in preventing oropharyngeal Candida albicans in the mouse oral cavity.

[0105] After intervention, the tongue tissue homogenates of mice were processed to evaluate the expression of TLR2, Myd88, IL-17, and IKBζ in each group. Figure 5 As shown in A, through real-time fluorescence quantification, it was found that the expression multiple of TLR2 in tongue tissue of model group after intervention was 2.38, while the expression multiple of S. salivarius CCFM1416 intervention group was 8.65, which was significantly different from that of model group (P < 0.01); Figure 5 As shown in B, real-time fluorescence quantification revealed that after the intervention, the expression multiple of Myd88 in the tongue tissue of the model group was 2.32, while the expression multiple of the S. salivarius CCFM1416 intervention group was 4.33, which was significantly different from that of the model group (P < 0.05); therefore, it is speculated that S. salivarius CCFM1416 can activate the upstream TLR2 / Myd88 pathway in the host and mediate the production of downstream antibacterial substances.

[0106] Similarly, if Figure 5 As shown in C, the IL-17 content in the model group after intervention was about 13.69 pg / mg, and the IL-17 content in the tongue tissue of the S. salivarius CCFM1416 intervention group after intervention was about 16.20 pg / mg, which was significantly different from the model group (P < 0.05). Figure 5 As shown in D, the expression of IKBζ in the blank group was about 81.11pg / mg, and the expression of IKBζ in the model group was about 67.73pg / mg, and there was no significant difference between the two. However, the expression of IKBζ in the tongue tissue of the S. salivarius CCFM1416 intervention group after intervention was about 122.28pg / mg, which was significantly different from that of the model group (P<0.01). Therefore, S. salivarius CCFM1416 can activate the anti-pathogenic bacteria infection pathways TLR2 / Myd88 and IL-17 / IKBζ in mice, upregulate the expression of downstream antimicrobial peptides, and play an anti-pathogenic bacteria infection role.

[0107] (4) Expression of antimicrobial peptides in mouse tongue tissue

[0108] After the intervention, the expression of antimicrobial peptide DEFB3 in the tongue tissue of mice was evaluated. Figure 6 As shown in the figure, after the intervention, the average expression of antimicrobial peptide DEFB3 in tongue tissue of the model group was about 13.64pg / mg, and the average expression of antimicrobial peptide DEFB3 in tongue tissue of the S. salivarius CCFM1416 group after intervention was about 25.21pg / mg, which was significantly higher than that of the model group (P<0.001). Therefore, it is speculated that S. salivarius CCFM1416 can activate the anti-pathogenic bacteria infection pathways TLR2 / Myd88 and IL-17 / IKBζ in mice, and upregulate the expression of the downstream product antimicrobial peptide DEFB3 (a homologue of human antimicrobial peptide HBD-2), thereby enhancing the host oral immunity and resisting the infection of oral pathogens.

[0109] (5) Histopathological analysis of mouse tongue

[0110] After the intervention, longitudinal sections of the mouse tongue tissue were observed. Figure 7 As shown in the figure, the filiform papillae on the dorsum of the tongue tissue of the blank group mice were neatly arranged, the epithelial stratum corneum was intact and smooth, the boundaries between the epithelial layers were clear, and there was no recruitment of inflammatory cells. In the model group, the epithelial stratum corneum was severely damaged, the filiform papillae on the dorsum of the tongue were basically non-existent, and there was a large number of inflammatory cells recruited and small abscesses formed in some locations. After intervention with S. salivarius CCFM1416, the pathological sections of the mouse tongue tissue were similar to those of the blank group, indicating that S. salivarius CCFM1416 can resist the invasion of oral pathogens and protect the oral mucosal tissue from damage to a certain extent.

[0111] (6) PAS staining analysis of mouse tongue tissue

[0112] After the intervention, PAS staining was performed on the tongue tissue of mice to observe the invasion of Candida albicans hyphae into the tongue tissue. Figure 8 As shown in the figure, no hyphae were observed to invade the tongue tissue by PAS staining in the blank group; PAS staining in the model group showed that a large number of hyphae invaded the epithelial layer of the tongue tissue, and a large number of inflammatory cells were recruited around these hyphae. Most of these hyphae invaded the deep layer of the epithelial tissue at a vertical or inclined angle to damage the tissue. After intervention with S. salivarius CCFM1416, the PAS staining of the mouse tongue tissue was similar to that of the blank group, indicating that S. salivarius CCFM1416 can resist the invasion of oral pathogens Candida albicans into oral mucosal tissues to a certain extent, thereby playing a role in resisting oral pathogen infection.

[0113] Although the present invention has been disclosed as above in the form of a preferred embodiment, it is not intended to limit the present invention. Anyone familiar with this technology can make various changes and modifications without departing from the spirit and scope of the present invention. Therefore, the scope of protection of the present invention should be based on the definition of the claims.

Claims

1. A strain of Streptococcus salivarius CCFM1416, characterized in that: The Streptococcus salivarius CCFM1416 was deposited in the Guangdong Provincial Microbiological Culture Collection Center on August 2, 2024, with the collection number GDMCCNo:64941.

2. A postbiotic prepared by using Streptococcus salivarius CCFM1416, characterized in that: The postbiotics include the inactivated bacteria of Streptococcus salivarius CCFM1416 and / or its lysate according to claim 1.

3. A microbial preparation containing the Streptococcus salivarius CCFM1416 according to claim 1 or the postbiotic according to claim 2.

4. A product containing the Streptococcus salivarius CCFM1416 according to claim 1, or the postbiotic according to claim 2, or the microbial preparation according to claim 3.

5. The product according to claim 4, characterized in that The products include health products, medicines or daily chemical products.

6. The product according to claim 5, characterized in that The product includes the Streptococcus salivarius CCFM1416 and conventional excipients; Optionally, the dosage form of the drug includes powder, granules, capsules, tablets, pills or oral liquid; Optionally, the daily chemical products include toothpaste, mouthwash and oral spray.

7. Use of the Streptococcus salivarius CCFM1416 according to claim 1, or the postbiotic according to claim 2, or the microbial preparation according to claim 3 in the preparation of medicines for preventing and / or treating pathogenic bacteria infections.

8. The use according to claim 7, characterized in that: The pathogenic bacteria include Candida albicans.

9. The use according to claim 8, characterized in that: The prevention and / or treatment of pathogenic bacteria infection includes: Promoting the expression of antimicrobial peptides; the antimicrobial peptides include HBD-2; and / or, activate the expression of TLR2 / Myd88 / IKBζ anti-infection pathway; and / or, activate the expression of the IL-17 / IKBζ anti-infection pathway; and / or, reducing the pathogenic bacterial load; and / or, improving the pathological condition at the site of infection.

10. The use according to claim 9, characterized in that: The infection site includes the oral cavity.